• Acute coronary syndrome (unstable angina/non-ST-elevation MI), including patients who will be managed medically and those who will undergo percutaneous coronary intervention (PCI).
• Patients undergoing PCI, including intracoronary stenting.

Contraindicated in:

• Hypersensitivity
• Active internal bleeding or history of bleeding within previous 30 days
• Severe uncontrolled hypertension (systolic BP >200 mm Hg and/or diastolic BP >110 mm Hg)
• Major surgical procedure within 6 wk
• History of hemorrhagic stroke or other stroke within 30 days
• Concurrent use of other glycoprotein IIb/IIIa receptor antagonists
• Platelet count <100,000/mm³
• Severe renal impairment (serum creatinine ≥4 mg/dL) or dependency on renal dialysis.

Use Cautiously in:

• Renal impairment (↓ infusion rate if CCr <50 mL/min)
• OB: Safety not established in pregnancy
• Lactation: Safety not established in breastfeeding
• Pedi: Safety and effectiveness not established in children
• Geri: ↑ risk of bleeding in older adults.

Noted for patients receiving heparin and aspirin in addition to eptifibatide

CV: hypotension.

Hemat: BLEEDING (INCLUDING GI AND INTRACRANIAL BLEEDING, HEMATURIA, AND HEMATOMAS), thrombocytopenia.

Drug-Drug:

• ↑ risk of bleeding with other drugs that affect hemostasis (heparins, warfarin, NSAIDs, thrombolytic agents, dipyridamole, clopidogrel, some cephalosporins, valproates).

Drug-Natural Products:

• ↑ bleeding risk with arnica, chamomile, clove, dong quai, feverfew, garlic, ginger, ginkgo, and Panax ginseng.

(Generic available)

• Solution for injection: 20 mg/10 mL; 75 mg/100 mL; 200 mg/100 mL;

Acute Coronary Syndrome

• IV (Adults): 180 mcg/kg (max = 22.6 mg) as a bolus dose, followed by 2 mcg/kg/min (max = 15 mg/hr) infusion until hospital discharge or initiation of coronary artery bypass graft surgery (up to 72 hr). If a patient is to undergo PCI, the infusion should be continued until hospital discharge or for up to 18–24 hr after the PCI, whichever comes first, allowing for up to 96 hr of therapy.

Percutaneous Coronary Intervention

• IV (Adults): 180 mcg/kg (max = 22.6 mg) as a bolus dose, immediately before PCI, followed by 2 mcg/kg/min (max = 15 mg/hr) infusion; a 2nd bolus of 180 mcg/kg (max = 22.6 mg) is given 10 min after 1st bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hr, whichever comes first (minimum of 12 hr).

Integrilin

• Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.

• Reduction in risk of death or new MI in patients with acute coronary syndrome.
• Reduction in risk of death, new MI, or need for urgent intervention in patients undergoing PCI.

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: 50% excreted by the kidneys.

Half-life: 2.5 hr.

(effects on platelet function)

†Inhibition is reversible following cessation of infusion.

• Inform patient of the purpose of eptifibatide.
• Instruct patient to notify health care professional immediately if any bleeding is noted.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

ep-ti-FIB-a-tide